{"id":"W4408979716","doi":"10.1016/s1556-0864(25)00330-2","title":"LBA3: Sites of relapse and subsequent therapy in the BR.31 phase III study of durvalumab vs placebo in resected stage IB-IIIA NSCLC","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Dalhousie University; Ottawa Hospital","funders":"Daiichi Sankyo Europe; National Cancer Institute; Sanofi K.K.; Bayer Yakuhin; Eli Lilly Japan; MSD K.K.; Chugai Pharmaceutical; Novartis Pharma; Ipsen; European Society for Medical Oncology; Pfizer Japan; Chinese Society of Clinical Oncology; Sociedad Española de Oncología Médica; Shionogi; Astellas Pharma; Eisai; Daiichi-Sankyo; Seagen; Yuhan; Astellas Foundation for Research on Metabolic Disorders; Taiho Pharmaceutical; Boehringer Ingelheim Japan; Pfizer; Incyte; AstraZeneca; Associazione Italiana di Oncologia Medica; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; American Society of Clinical Oncology; Otsuka Pharmaceutical; International Association for the Study of Lung Cancer; BeiGene; Sanofi; Amgen","keywords":"Durvalumab; Medicine; Stage (stratigraphy); Placebo; Oncology; Internal medicine; Pathology; Cancer; Alternative medicine; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001564054,0.001214535,0.002516549,0.0003006694,0.0004312669,0.0009769617,0.0009449782,0.0009614392,0.003846181],"category_scores_gemma":[0.0008604095,0.0004490384,0.001749639,0.0002885379,0.0007289258,0.0007591011,0.0003424227,0.003350094,0.0006741558],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001179339,"about_ca_system_score_gemma":0.001544678,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002578287,"about_ca_topic_score_gemma":0.009496346,"domain_scores_codex":[0.9995545,0.0002424269,0.0000186164,0.00004915043,0.00003392102,0.0001014011],"domain_scores_gemma":[0.9995077,0.0001338934,0.0001105577,0.00003970287,0.00001906004,0.0001890988],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9241509,0.008852632,0.002531793,0.0005298452,0.001245755,0.00007166034,0.00008760888,0.001261075,0.01278993,0.0001964877,0.002008411,0.04627398],"study_design_scores_gemma":[0.7350569,0.2376776,0.01821896,0.00006644402,0.00141345,0.000203146,0.000112123,0.001990187,0.002973971,0.0003694718,0.0018697,0.00004795977],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931613,0.003382585,0.0001898355,0.0004413683,0.0001653824,0.000344466,0.0008590291,0.0000759811,0.001379984],"genre_scores_gemma":[0.9944791,0.001403819,0.0004292927,0.0003176635,0.0001098971,0.0004816304,0.0009590764,0.00002445303,0.001795068],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003846181,"threshold_uncertainty_score":0.01286674,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05211819168494634,"score_gpt":0.4760523037186633,"score_spread":0.4239341120337169,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}